Aaron Wealth Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$910K Buy
10,058
+684
+7% +$57.3K 0.05% 268
2026
Q1
$751K Sell
9,374
-15
-0.2% -$1.24K 0.04% 289
2025
Q4
$800K Sell
9,389
-98
-1% -$8.04K 0.04% 297
2025
Q3
$738K Buy
9,487
+3,484
+58% +$272K 0.04% 305
2025
Q2
$469K Buy
6,003
+390
+7% +$29.1K 0.05% 249
2025
Q1
$407K Sell
5,613
-675
-11% -$48.3K 0.05% 259
2024
Q4
$466K Buy
6,288
+2,155
+52% +$151K 0.05% 218
2024
Q3
$273K Buy
+4,133
New +$300K 0.03% 325
2023
Q3
Sell
-3,262
Closed -$308K 266
2023
Q2
$308K Buy
3,262
+405
+14% +$35.2K 0.04% 201
2023
Q1
$236K Buy
+2,857
New +$225K 0.03% 222
2022
Q4
Sell
-2,967
Closed -$245K 251
2022
Q3
$245K Buy
2,967
+839
+39% +$80.7K 0.05% 179
2022
Q2
$202K Sell
2,128
-261,329
-99% -$27.1M 0.05% 182
2022
Q1
$2.24M Buy
263,457
+261,191
+11,527% +$29.3M 0.03% 218
2021
Q4
$293K Buy
2,266
+277
+14% +$32.3K 0.08% 145
2021
Q3
$225K Buy
+1,989
New +$227K 0.06% 146

Other funds holding EW

Aaron Wealth Advisors's EW Position: Q2 2026 in Review

Aaron Wealth Advisors increased its Edwards Lifesciences (EW) stake by 7.3% in Q2 2026, buying an estimated $57.3K and bringing the position to 10,058 shares worth $910K. The position accounts for 0.05% of the portfolio, ranked #268.

Aaron Wealth Advisors first reported a position in EW in Q3 2021 and has held it in 15 quarters since. The position peaked at $2.24M in Q1 2022. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Aaron Wealth Advisors held 10,058 shares of Edwards Lifesciences worth $910K as of Q2 2026.
  • Aaron Wealth Advisors bought 684 Edwards Lifesciences shares in Q2 2026, an estimated $57.3K.
  • Edwards Lifesciences made up 0.05% of Aaron Wealth Advisors's portfolio in Q2 2026, its #268 holding.
  • Aaron Wealth Advisors first reported a position in Edwards Lifesciences in Q3 2021 and has held it in 15 quarters since.
  • Aaron Wealth Advisors's Edwards Lifesciences position peaked at $2.24M in Q1 2022.
  • 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Aaron Wealth Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.